FRI0009 Infliximab in the treatment of rheumatoid arthritis (ra): referral patterns, response to treatment, and adverse events in a real world setting

Abstract

BackgroundObjectives Leflunomide (LEF) is a disease modifying antirheumatic prodrug with immunomodulating, antiproliferative and antiinflammatory properties. We studied our first daily practice experience with LEF in the Outpatient Department of Rheumatology. Methods In this prospective study we included all consecutive patients with active rheumatoid arthritis (RA), starting treatment